Barcelona, Spain

Eleonora Marcucci

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Pharma Mar, S.a.. Active years: 2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eleonora Marcucci. Retrieved from https://idiyas.com/inventor/eleonora-marcucci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Eleonora Marcucci: Innovator in Antitumoral Compounds

Introduction

Eleonora Marcucci is a prominent inventor based in Barcelona, Spain. She has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumoral compounds. Her innovative work has the potential to impact cancer treatment positively.

Latest Patents

Marcucci holds a patent for antitumoral compounds, specifically those described as Formula I, along with their pharmaceutically acceptable salts, derivatives, tautomers, prodrugs, or stereoisomers. This patent is crucial as it outlines the compounds' utility as antitumor agents, showcasing her commitment to advancing medical science.

Career Highlights

Eleonora Marcucci is associated with Pharma Mar, S.A., a company known for its focus on innovative cancer therapies. Her work at Pharma Mar has allowed her to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Marcucci collaborates with esteemed colleagues, including Judit Tulla-Puche and Núria Bayó-Puxan. These partnerships enhance her research efforts and foster a collaborative environment for innovation.

Conclusion

Eleonora Marcucci is a trailblazer in the field of antitumoral research, with a patent that underscores her innovative spirit. Her work at Pharma Mar and collaborations with other experts highlight her dedication to improving cancer treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…